Adrenomed
Phase 3Precision medicine approach: Targeted treatment using two biomarkers (bio-ADM and DPP3) identifies septic shock patients most likely to benefit from enibarcimab treatment Promising clinical results:
Founded
2009
Focus
AntibodiesBiologics
About
Precision medicine approach: Targeted treatment using two biomarkers (bio-ADM and DPP3) identifies septic shock patients most likely to benefit from enibarcimab treatment Promising clinical results:
Funding History
4Total raised: $84M
Series C$40MBoehringer Ingelheim Venture FundJun 15, 2021
Series B$27MBoehringer Ingelheim Venture FundJun 15, 2018
Series A$15MBoehringer Ingelheim Venture FundJun 15, 2015
Seed$2MHigh-Tech GründerfondsJun 15, 2011
Company Info
TypePrivate
Founded2009
LocationHennigsdorf, Germany
StagePhase 3
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile